Measurable residual disease study through three different methods can anticipate relapse and guide pre-emptive therapy in childhood acute myeloid leukemia.
Eduardo Ramos ElbalJosé Luis FusterJosé Antonio CampilloAna María GaleraMar Bermúdez CortésMaría Esther LlinaresIrene JiménezMercedes PlazaHelios Martínez BanaclochaJosé Antonio GaliánMiguel Blanquer BlanquerMaría Victoria Martínez SánchezManuel MuroAlfredo MinguelaPublished in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2023)
MFC, FISH and PCR are complementary methods that can anticipate relapse of childhood AML by weeks to several months. However, in our series, pre-emptive therapies were not able to prevent disease progression. Therefore, more sensitive MRD monitoring methods that further anticipate relapse and more effective pre-emptive therapies are needed.